Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Protara Therapeutics (NASDAQ:TARA) in a research note released on Friday morning, Marketbeat Ratings reports. The firm issued an overweight rating on the stock.

TARA has been the topic of several other reports. Guggenheim reissued a “buy” rating and issued a $20.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Thursday, March 6th. Finally, Lifesci Capital assumed coverage on shares of Protara Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $22.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $22.50.

Protara Therapeutics Stock Up 7.2 %

Shares of NASDAQ TARA opened at $4.31 on Friday. The company has a market capitalization of $88.92 million, a PE ratio of -1.53 and a beta of 1.69. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48. The firm has a fifty day simple moving average of $4.42 and a 200 day simple moving average of $3.47.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09. As a group, equities analysts expect that Protara Therapeutics will post -3.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Protara Therapeutics

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in Protara Therapeutics by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company’s stock valued at $948,000 after purchasing an additional 9,553 shares during the period. Commonwealth Equity Services LLC grew its holdings in shares of Protara Therapeutics by 90.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock valued at $195,000 after buying an additional 17,572 shares during the last quarter. HBK Investments L P bought a new stake in shares of Protara Therapeutics during the fourth quarter worth about $106,000. Squarepoint Ops LLC acquired a new stake in shares of Protara Therapeutics in the 4th quarter worth about $110,000. Finally, Dimensional Fund Advisors LP bought a new position in Protara Therapeutics in the 4th quarter valued at about $111,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.